COVA 322

Drug Profile

COVA 322

Alternative Names: Bispecific anti-TNF/IL-17A FynomAb; COVA322

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Covagen
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Bispecific antibodies
  • Mechanism of Action Interleukin-17 inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Plaque psoriasis
  • Preclinical Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis

Most Recent Events

  • 26 Feb 2016 Covagen terminates a phase-I/II trial in Plaque psoriasis in Germany (NCT02243787) (IV)
  • 10 Feb 2016 Phase-I/II development is ongoing in Germany
  • 25 Aug 2014 Cilag GmbH International acquires Covagen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top